188 related articles for article (PubMed ID: 34492588)
1. Overexpression of transposable elements is associated with immune evasion and poor outcome in colorectal cancer.
Zhu X; Fang H; Gladysz K; Barbour JA; Wong JWH
Eur J Cancer; 2021 Nov; 157():94-107. PubMed ID: 34492588
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
3. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
[TBL] [Abstract][Full Text] [Related]
4. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
[TBL] [Abstract][Full Text] [Related]
5. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
6. Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines.
Owaki R; Deguchi T; Konnai S; Maekawa N; Okagawa T; Hosoya K; Kim S; Sunaga T; Okumura M
Vet Comp Oncol; 2023 Jun; 21(2):279-290. PubMed ID: 36802270
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
8. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.
Fakih M; Ouyang C; Wang C; Tu TY; Gozo MC; Cho M; Sy M; Longmate JA; Lee PP
J Clin Invest; 2019 Oct; 129(10):4464-4476. PubMed ID: 31524634
[TBL] [Abstract][Full Text] [Related]
9. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
10. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
11. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
12. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E
BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662
[TBL] [Abstract][Full Text] [Related]
13. The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the 'immunoreactive' microenvironment of colorectal carcinoma.
Prall F; Hühns M
Histopathology; 2017 Sep; 71(3):366-374. PubMed ID: 28383777
[TBL] [Abstract][Full Text] [Related]
14. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.
Kim JH; Park HE; Cho NY; Lee HS; Kang GH
Br J Cancer; 2016 Aug; 115(4):490-6. PubMed ID: 27404452
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1.
Ho HL; Chou TY; Yang SH; Jiang JK; Chen WS; Chao Y; Teng HW
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1785-1794. PubMed ID: 31129768
[TBL] [Abstract][Full Text] [Related]
18. S100A14: A novel negative regulator of cancer stemness and immune evasion by inhibiting STAT3-mediated programmed death-ligand 1 expression in colorectal cancer.
Min HY; Cho J; Sim JY; Boo HJ; Lee JS; Lee SB; Lee YJ; Kim SJ; Kim KP; Park IJ; Hong SM; Zhang XL; Zhang ZG; Park RW; Lee HY
Clin Transl Med; 2022 Jul; 12(7):e986. PubMed ID: 35858011
[TBL] [Abstract][Full Text] [Related]
19. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
20. Ataxia telangiectasia mutated kinase inhibition promotes irradiation-induced PD-L1 expression in tumour-associated macrophages through IFN-I/JAK signalling pathway.
Gao Y; Li Y; Lin Z; Zeng Y; Huang Z; Han L; Zhong Y; Gong Y; Wu Q; Xie C
Immunology; 2023 Feb; 168(2):346-361. PubMed ID: 36326481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
